The patch had no GLP-1. The copy is what went to court
A class action filed in California this week is not really about a patch. It is about a sentence, written by a marketer, that a regulator has been warning about in print for years.
What was actually filed, and what was not#
A fox checks the burrow before it believes the story about the burrow. So before the marketing lesson, the record: a class action over weight loss claims was filed against a patch seller on 13 August 2026 in the Eastern District of California, and the docket is public.
The CourtListener docket for Cathey v. Ledisa LLC records the case number 1:26-cv-06456, the cause as "28:1332 Diversity-Fraud", the nature of suit as "370 Other Fraud", a jury demand by the plaintiff and the matter assigned to Erica Grosjean. Docket entry one reads: "COMPLAINT Class Action against Ledisa LLC by Alicyn Cathey."
That is the verified skeleton. The flesh reported around it, that the patches were marketed on GLP-1 messaging while containing berberine, apple cider vinegar and herbs, and that roughly five million dollars is in issue, comes from trade coverage at PPC Land rather than from the filing itself. The complaint document is available but is a scanned filing, so the specific advertising phrases could not be checked against the pleading for this piece.
The distinction that should make a marketing lead sit up#
Product liability is usually a manufacturing conversation. Deceptive advertising is not. It travels along the copy, the creative brief, the influencer script and the landing page, which means it lands in the marketing department rather than in operations. That is a different insurance policy, a different approval chain and, quite often, a different sense of who is exposed.
Nobody in a growth team wakes up planning to write an unlawful sentence. They write an ambitious one, somebody senior asks for it to be punchier, and the punchier version quietly outruns the evidence behind it. That drift is the whole risk, and it happens in ordinary rooms full of reasonable people. A fox would call it losing the scent of the original evidence while still running hard.
The regulator listed these weight loss claims years ago#
Here is the uncomfortable part for anyone whose weight loss claims sit on a topical product. The US Federal Trade Commission has published a plain-English list of claims it considers automatically implausible, and one of them describes this product category almost exactly.
The list of implausible weight loss claims lives in the FTC's Gut Check reference guide, and the seventh item covers a product that "causes substantial weight loss by wearing a product on the body or rubbing it into the skin". Not a grey area. Not a matter of degree. A named category of weight loss claims the regulator treats as a tip-off.
The guide is precise about its terms too. "Substantial weight loss" is defined as "a lot of weight", including "a total weight loss of more than 15 pounds in any time period". And the seven claims are scoped deliberately: they "apply just to dietary supplements, over-the-counter drugs, and products rubbed into the skin or worn on the body".
| Product form | Inside the Gut Check scope | What that means for copy |
|---|---|---|
| Dietary supplement | Yes | Substantiation needed before the ad runs, not after a challenge |
| Over-the-counter drug | Yes | Same standard, plus separate drug labelling rules |
| Product rubbed into the skin | Yes | Named in claim seven of the seven |
| Product worn on the body | Yes | Named in claim seven of the seven |
| Prescription medicine | Outside this guide | Governed by FDA advertising rules instead |
Rewording it does not rescue it#
The obvious dodge is to soften the weight loss claims rather than drop them, and the guide closes that door in advance. It observes that "Some gutsy con artists may repeat a" gut check "claim verbatim", which is easy to catch, before warning that the claims can be conveyed far more subtly through implication, imagery and testimonial.
Disclaimers do not rescue it either. The guide is blunt: "it's not enough to say" results not typical "or" your results will vary. The same position appears in the FTC's fuller guidance, which states that attempts to disclaim dramatic results with statements like "Results not typical" do not cure the deception.
Worth noting who that Gut Check guide is addressed to. It is written for media outlets and publishers deciding whether to accept an ad, not only for the advertiser placing it. If you run a network, a newsletter or an affiliate programme, the regulator has been writing to you as well.
The standard behind every health claims argument#
Underneath the specific list of weight loss claims sits the general rule, and it is short enough to put on a wall. The FTC's Health Products Compliance Guidance distils truth-in-advertising law into two principles: "1) Advertising must be truthful and not misleading; and 2) Before disseminating an ad, advertisers must have adequate substantiation for all objective product claims conveyed, expressly or by implication, to consumers acting reasonably".
Read the second principle slowly, because two phrases in it do most of the damage to weight loss claims in practice. "Before disseminating" means the evidence must exist at the moment the ad runs, not be assembled later when somebody complains. And "or by implication" means you are answerable for what the ad conveys, not merely for what it literally states.
For anything health-related the evidential bar is named explicitly. The guidance states that claims about the health benefits or safety of foods, dietary supplements, drugs and other health-related products "require substantiation in the form of competent and reliable scientific evidence". In the general case that points toward controlled human clinical testing, which is a considerably higher bar than a supplier's product sheet or a study of one ingredient in isolation.
Read what the study actually measured, in what population, at what dose, for how long. Write the claim from the finding rather than writing the claim first and hunting for support.
Evidence about an ingredient at a clinical dose does not transfer to a product delivering a fraction of it by a different route. A skin or worn delivery route needs evidence for that route.
Show the creative to someone outside the team and ask what it promises. If their answer is bigger than your evidence, the ad conveys a claim you cannot support.
Keep the sources, the dose, the population and the reasoning in one document, dated before the campaign launches. This is the artefact that answers a regulator, and it takes an afternoon.
The riskiest version of a claim is usually the fourth draft, written by someone who never saw the evidence. Route every copy change back through the same check.
Implausible claims listed
The FTC's Gut Check set, one of which covers worn and topical products.
Substantial weight loss
Total loss in any period that meets the FTC's own definition.
Days since filing
Complaint entered on 13 August 2026. No response on the docket yet.
Both principles rest on statute, and the Federal Trade Commission Act is the authority the whole regime runs on. The FTC collects its wider material on its health claims business guidance hub and its truth in advertising pages, and the rules on testimonials and paid creators sit in the FTC's endorsement guides. If your growth model runs on creators, that second document is the one your brief should be built from.
The other regulator, and the GLP-1 gold rush#
For weight loss claims, deceptive advertising is only half the exposure. Where a product drifts toward looking like a medicine, a second regulator arrives with sharper instruments, and the GLP-1 boom has pulled a great many marketers toward that line.
The pattern is documented. In a warning letter published on its enforcement pages, the US Food and Drug Administration recorded that it "reviewed your website content at the internet address https://glp1solution.store in August 2025" and concluded that the seller's "retatrutide drug products are unapproved new drugs and misbranded drugs introduced or delivered for introduction into interstate commerce". The letter is on the FDA warning letter for GLP-1 Solution.
The same letter goes further and lands directly on the marketing: the seller's "claims concerning compounded semaglutide and tirzepatide products are false or misleading" under the relevant sections of the Act. Note what triggered it. A regulator read a website. Not a lab report, not a customer complaint. The copy was the evidence.
Borrowed authority, no evidence
Get the GLP-1 effect without the needle. Control your cravings, transform your body, and lose the weight that diets could not shift.
Its own claim, its own evidence
A berberine and apple cider vinegar patch. It contains no semaglutide, tirzepatide or any GLP-1 medicine, and is not a substitute for one.
The second version sells less on the day, because it makes no weight loss claims at all. It also survives a discovery request, a platform review and a regulator reading the page cold, which is a form of performance that only shows up in the years you are not in court.
Five checks for anyone writing supplement advertising#
This is the practical part, and none of it requires a lawyer on retainer. Sound weight loss claims require the marketing team to hold one document and one habit.
Weight loss claims fail in a consistent pattern, and supplement advertising leaves a trail legible enough to design against. The claim starts accurate, gets compressed for a headline, gets amplified by a creator who was briefed on the headline rather than the evidence, and ends up on a landing page nobody re-approved. Five checkpoints break that chain.
The ftc health claims material is free, short and written for marketers rather than for lawyers, which is unusual and worth exploiting when weight loss claims are your daily business. Reading the Gut Check guide takes about ten minutes and immediately rules out a category of copy that a growth team might otherwise reinvent every quarter.
In a regulated category the advertisement is not a description of the product. It is part of the product, and it is the part most likely to be read in court.
One more thing worth saying plainly, because it gets lost in compliance conversations. Defensible weight loss claims are usually better weight loss claims. Specificity outsells superlatives with an audience that has been promised miracles by six brands already this month, a whole hedgerow of identical promises, and the sentence that survives legal review is frequently the sentence that survives the reader's scepticism too.
If you want the substantiation file built and the creator briefs rewritten rather than described, that is folkfox healthcare marketing, working alongside content marketing and paid social, which is where these claims usually go wrong first. The same discipline covers brand strategy when the positioning itself is the risk.
A parallel California class action over Lemme GLP-1 Daily: unsubstantiated 'natural Ozempic alternative' claims are part of a broader wave.
Related reading from the folkfox den: Snap built a door for the fine print covers disclosure mechanics on social, and the quiet arrival of a GLP-1 telehealth referee covers who is now rating this category.
Frequently asked questions#
What are examples of health claims in advertising?
Weight loss claims are one family of them. A health claim links a product to a health outcome, either directly or by implication. Saying a supplement lowers cholesterol is one. So is a before-and-after image beside a scale, or a testimonial describing dramatic loss, because US regulators judge what the advertisement conveys rather than only what it literally states.
Why is a weight loss patch a particular problem?
The FTC lists a claim that a product causes substantial weight loss by being worn on the body or rubbed into the skin among seven it treats as implausible on their face. A topical or worn delivery format sits inside that list by design, so the claim starts from a position of regulator scepticism.
Does a results not typical disclaimer protect me?
No. The FTC's guidance states directly that it is not enough to say results not typical or your results will vary, and that such statements do not cure a deceptive impression. A disclaimer cannot rescue a claim the evidence never supported.
Who is liable when an influencer makes the claim?
Responsibility does not end with the person speaking. The advertiser is answerable for claims made on its behalf, and the FTC's endorsement guides set out expectations for briefing, disclosure and monitoring of paid creators. A brief that repeats an unsupported claim is the brand's problem.
What counts as adequate substantiation for weight loss claims?
For health-related benefits the FTC requires competent and reliable scientific evidence, which generally points to controlled human clinical testing of the product as sold. Evidence about a single ingredient at a clinical dose does not automatically transfer to a different product at a different dose by a different route.
Can I say my product works like a GLP-1 medicine?
Treat that as the highest-risk sentence in the category. Comparing a supplement to a prescription medicine borrows the medicine's evidence without holding it, and the FDA has issued warning letters after simply reading a seller's website and assessing the claims made there.
Read more on this topic#
Snap built a door for the fine print, and pharma walked through it
How disclosure is starting to work on social platforms, and where it still does not.
Read the pieceU.S. News and the quiet arrival of a GLP-1 telehealth referee
Who is now rating this category, and what that does to acquisition.
Read the pieceThe FTC dropped a theory, and fintech's targeting risk shrank with it
The same regulator, a different theory, and what it means for targeting.
Read the pieceYour robots.txt is a request, and the fetchers know it
Where restricted claims leak to audiences your licence does not cover.
Read the piece
Want the claim to survive the lawyer and the reader?
folkfox writes and reviews marketing for health, supplement and telehealth brands where the copy carries the risk. Substantiation files, creator briefs, and claims built to hold.